Christopher C Giza1,2, Michael McCrea3, Daniel Huber3, Kenneth L Cameron4,5, Megan N Houston4, Jonathan C Jackson6, Gerald McGinty6, Paul Pasquina5, Steven P Broglio7, Alison Brooks8, John DiFiori9, Stefan Duma10, Jaroslaw Harezlak11, Joshua Goldman12, Kevin Guskiewicz13, Thomas W McAllister14, David McArthur1, Timothy B Meier3, Jason P Mihalik13, Lindsay D Nelson3, Steven Rowson10, Jessica Gill15, Tatiana Foroud14, Barry Katz14, Andrew Saykin14, Darren E Campbell6, Steven Svoboda16. 1. Department of Neurosurgery, UCLA Steve Tisch BrainSPORT Program, University of California, Los Angeles, Los Angeles. 2. Department of Pediatrics, UCLA Steve Tisch BrainSPORT Program, University of California, Los Angeles, Los Angeles. 3. Department of Neurosurgery, Medical College of Wisconsin, Milwaukee. 4. John A. Feagin Sports Medicine Fellowship, Keller Army Community Hospital, West Point, New York. 5. Department of Physical Medicine and Rehabilitation, Uniformed Services University, Bethesda, Maryland. 6. US Air Force Academy, Colorado Springs, Colorado. 7. Michigan Concussion Center, University of Michigan, Ann Arbor. 8. Department of Orthopedics and Rehabilitation, School of Medicine and Public Health, University of Wisconsin, Madison. 9. Hospital for Special Surgery, New York, New York. 10. Department of Biomedical Engineering, Virginia Tech, Blacksburg. 11. Department of Epidemiology and Biostatistics School of Public Health-Bloomington, Indiana University, Bloomington. 12. Department of Family Medicine, UCLA Steve Tisch BrainSPORT Program, University of California, Los Angeles, Los Angeles. 13. Matthew Gfeller Sport-Related Traumatic Brain Injury Research Center, Department of Exercise and Sport Science, University of North Carolina at Chapel Hill, Chapel Hill. 14. Department of Psychiatry, Indiana University School of Medicine, Indianapolis. 15. National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland. 16. US Military Academy at West Point, New York.
Abstract
Importance: Validation of protein biomarkers for concussion diagnosis and management in military combative training is important, as these injuries occur outside of traditional health care settings and are generally difficult to diagnose. Objective: To investigate acute blood protein levels in military cadets after combative training-associated concussions. Design, Setting, and Participants: This multicenter prospective case-control study was part of a larger cohort study conducted by the National Collegiate Athletic Association and the US Department of Defense Concussion Assessment Research and Education (CARE) Consortium from February 20, 2015, to May 31, 2018. The study was performed among cadets from 2 CARE Consortium Advanced Research Core sites: the US Military Academy at West Point and the US Air Force Academy. Cadets who incurred concussions during combative training (concussion group) were compared with cadets who participated in the same combative training exercises but did not incur concussions (contact-control group). Clinical measures and blood sample collection occurred at baseline, the acute postinjury point (<6 hours), the 24- to 48-hour postinjury point, the asymptomatic postinjury point (defined as the point at which the cadet reported being asymptomatic and began the return-to-activity protocol), and 7 days after return to activity. Biomarker levels and estimated mean differences in biomarker levels were natural log (ln) transformed to decrease the skewness of their distributions. Data were collected from August 1, 2016, to May 31, 2018, and analyses were conducted from March 1, 2019, to January 14, 2020. Exposure: Concussion incurred during combative training. Main Outcomes and Measures: Proteins examined included glial fibrillary acidic protein, ubiquitin C-terminal hydrolase-L1, neurofilament light chain, and tau. Quantification was conducted using a multiplex assay (Simoa; Quanterix Corp). Clinical measures included the Sport Concussion Assessment Tool-Third Edition symptom severity evaluation, the Standardized Assessment of Concussion, the Balance Error Scoring System, and the 18-item Brief Symptom Inventory. Results: Among 103 military service academy cadets, 67 cadets incurred concussions during combative training, and 36 matched cadets who engaged in the same training exercises did not incur concussions. The mean (SD) age of cadets in the concussion group was 18.6 (1.3) years, and 40 cadets (59.7%) were male. The mean (SD) age of matched cadets in the contact-control group was 19.5 (1.3) years, and 25 cadets (69.4%) were male. Compared with cadets in the contact-control group, those in the concussion group had significant increases in glial fibrillary acidic protein (mean difference in ln values, 0.34; 95% CI, 0.18-0.50; P < .001) and ubiquitin C-terminal hydrolase-L1 (mean difference in ln values, 0.97; 95% CI, 0.44-1.50; P < .001) levels at the acute postinjury point. The glial fibrillary acidic protein level remained high in the concussion group compared with the contact-control group at the 24- to 48-hour postinjury point (mean difference in ln values, 0.22; 95% CI, 0.06-0.38; P = .007) and the asymptomatic postinjury point (mean difference in ln values, 0.21; 95% CI, 0.05-0.36; P = .01). The area under the curve for all biomarkers combined, which was used to differentiate cadets in the concussion and contact-control groups, was 0.80 (95% CI, 0.68-0.93; P < .001) at the acute postinjury point. Conclusions and Relevance: This study's findings indicate that blood biomarkers have potential for use as research tools to better understand the pathobiological changes associated with concussion and to assist with injury identification and recovery from combative training-associated concussions among military service academy cadets. These results extend the previous findings of studies of collegiate athletes with sport-associated concussions.
Importance: Validation of protein biomarkers for concussion diagnosis and management in military combative training is important, as these injuries occur outside of traditional health care settings and are generally difficult to diagnose. Objective: To investigate acute blood protein levels in military cadets after combative training-associated concussions. Design, Setting, and Participants: This multicenter prospective case-control study was part of a larger cohort study conducted by the National Collegiate Athletic Association and the US Department of Defense Concussion Assessment Research and Education (CARE) Consortium from February 20, 2015, to May 31, 2018. The study was performed among cadets from 2 CARE Consortium Advanced Research Core sites: the US Military Academy at West Point and the US Air Force Academy. Cadets who incurred concussions during combative training (concussion group) were compared with cadets who participated in the same combative training exercises but did not incur concussions (contact-control group). Clinical measures and blood sample collection occurred at baseline, the acute postinjury point (<6 hours), the 24- to 48-hour postinjury point, the asymptomatic postinjury point (defined as the point at which the cadet reported being asymptomatic and began the return-to-activity protocol), and 7 days after return to activity. Biomarker levels and estimated mean differences in biomarker levels were natural log (ln) transformed to decrease the skewness of their distributions. Data were collected from August 1, 2016, to May 31, 2018, and analyses were conducted from March 1, 2019, to January 14, 2020. Exposure: Concussion incurred during combative training. Main Outcomes and Measures: Proteins examined included glial fibrillary acidic protein, ubiquitin C-terminal hydrolase-L1, neurofilament light chain, and tau. Quantification was conducted using a multiplex assay (Simoa; Quanterix Corp). Clinical measures included the Sport Concussion Assessment Tool-Third Edition symptom severity evaluation, the Standardized Assessment of Concussion, the Balance Error Scoring System, and the 18-item Brief Symptom Inventory. Results: Among 103 military service academy cadets, 67 cadets incurred concussions during combative training, and 36 matched cadets who engaged in the same training exercises did not incur concussions. The mean (SD) age of cadets in the concussion group was 18.6 (1.3) years, and 40 cadets (59.7%) were male. The mean (SD) age of matched cadets in the contact-control group was 19.5 (1.3) years, and 25 cadets (69.4%) were male. Compared with cadets in the contact-control group, those in the concussion group had significant increases in glial fibrillary acidic protein (mean difference in ln values, 0.34; 95% CI, 0.18-0.50; P < .001) and ubiquitin C-terminal hydrolase-L1 (mean difference in ln values, 0.97; 95% CI, 0.44-1.50; P < .001) levels at the acute postinjury point. The glial fibrillary acidic protein level remained high in the concussion group compared with the contact-control group at the 24- to 48-hour postinjury point (mean difference in ln values, 0.22; 95% CI, 0.06-0.38; P = .007) and the asymptomatic postinjury point (mean difference in ln values, 0.21; 95% CI, 0.05-0.36; P = .01). The area under the curve for all biomarkers combined, which was used to differentiate cadets in the concussion and contact-control groups, was 0.80 (95% CI, 0.68-0.93; P < .001) at the acute postinjury point. Conclusions and Relevance: This study's findings indicate that blood biomarkers have potential for use as research tools to better understand the pathobiological changes associated with concussion and to assist with injury identification and recovery from combative training-associated concussions among military service academy cadets. These results extend the previous findings of studies of collegiate athletes with sport-associated concussions.
Authors: Mark P Kelly; Rodney L Coldren; Robert V Parish; Michael N Dretsch; Michael L Russell Journal: Arch Clin Neuropsychol Date: 2012-04-03 Impact factor: 2.813
Authors: Kimbra Kenney; Bao-Xi Qu; Chen Lai; Christina Devoto; Vida Motamedi; William C Walker; Harvey S Levin; Tracy Nolen; Elisabeth A Wilde; Ramon Diaz-Arrastia; Jessica Gill Journal: Brain Inj Date: 2018-06-11 Impact factor: 2.311
Authors: Jan P Vandenbroucke; Erik von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger Journal: Int J Surg Date: 2014-07-18 Impact factor: 6.071
Authors: Jonathan I Stuart; Ian L Hudson; Simon A Sarkisian; Michael P Simpson; Benjamin P Donham Journal: Mil Med Date: 2018-09-01 Impact factor: 1.437
Authors: Alex P Di Battista; Katherine A Moes; Maria Y Shiu; Michael G Hutchison; Nathan Churchill; Scott G Thomas; Shawn G Rhind Journal: Front Physiol Date: 2018-09-28 Impact factor: 4.566
Authors: Linda Papa; Gretchen M Brophy; Robert D Welch; Lawrence M Lewis; Carolina F Braga; Ciara N Tan; Neema J Ameli; Marco A Lopez; Crystal A Haeussler; Diego I Mendez Giordano; Salvatore Silvestri; Philip Giordano; Kurt D Weber; Crystal Hill-Pryor; Dallas C Hack Journal: JAMA Neurol Date: 2016-05-01 Impact factor: 18.302
Authors: Pashtun Shahim; Yelverton Tegner; Bengt Gustafsson; Magnus Gren; Johan Ärlig; Martin Olsson; Niklas Lehto; Åsa Engström; Kina Höglund; Erik Portelius; Henrik Zetterberg; Kaj Blennow Journal: JAMA Neurol Date: 2016-11-01 Impact factor: 18.302
Authors: George Anis Sarkis; Tian Zhu; Zhihui Yang; Xue Li; Yuan Shi; Richard Rubenstein; Richard A Yost; Geoffrey T Manley; Kevin K Wang Journal: Biomark Med Date: 2021-10-22 Impact factor: 2.851
Authors: Michael Goutnik; Joel Goeckeritz; Zackary Sabetta; Tala Curry; Matthew Willman; Jonathan Willman; Theresa Currier Thomas; Brandon Lucke-Wold Journal: Biomechanics (Basel) Date: 2022-09-23
Authors: Jacqueline R Kulbe; Sonia Jain; Lindsay D Nelson; Frederick K Korley; Pratik Mukherjee; Xiaoying Sun; David O Okonkwo; Joseph T Giacino; Mary J Vassar; Claudia S Robertson; Michael A McCrea; Kevin K W Wang; Nancy Temkin; Christine L Mac Donald; Sabrina R Taylor; Adam R Ferguson; Amy J Markowitz; Ramon Diaz-Arrastia; Geoffrey T Manley; Murray B Stein Journal: Neuropsychopharmacology Date: 2022-06-18 Impact factor: 8.294
Authors: Linda Papa; Alexa E Walter; James R Wilkes; Hunter S Clonts; Brian Johnson; Semyon M Slobounov Journal: J Neurotrauma Date: 2022-09-01 Impact factor: 4.869